<DOC>
	<DOCNO>NCT01598584</DOCNO>
	<brief_summary>Depression anxiety accompany advance cancer . The effect anti-anxiety depression evaluate special cancer . Mirtazapine drug anti-anxiety depression high risk increase weight . So investigators assume Mirtazapine would improve anxiety depression metastasis pancreas cancer also would improve appetite patient would improve dyscrasia pancreas cancer patient . The drug may improve quality life advance pancreatic cancer short survival .</brief_summary>
	<brief_title>Mirtazapine Plus Gemcitabine Versus Gemcitabine Metastasis Pancreatic Cancer</brief_title>
	<detailed_description>The investigator design phase II/III trial compare Mirtazapine plus gemcitabine gemcitabine metastasis pancreatic cancer . The investigator plan enroll 33 patient arm randomization . The inclusion criterion include : 1 . Patients shall normal organic function liver function , Cardiac function renal function . 2 . Before enrolled , anxious depression state evaluate Hamilton degree depression anxiety scale . Only patient definite depression and/or anxiety consider participate trial . 3 . Pancreatic cancer patient ECOG 1～2 score enrol . 4 . Patients expect live short 1.5 month The investigator evaluate quality life SF-36 scale primary outcome . The second outcome include anxious depression score , objective response rate , progress free survival , overall Survival chemotherapy induce nausea vomiting .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>1 . Patients pancreatic cancer shall normal organic function liver function , cardiac function renal function . 2 . Before enrolled , anxious depression state evaluate Hamilton degree depression anxiety scale . Only patient definite depression and/or anxiety consider participate trial . 3 . Pancreatic cancer patient ECOG 1～2 score enrol . 4 . Patients expect live short 1.5 month 1 . Patients receive anticancer drug ; 2 . Patients discontinue anticancer drug le 4 week , patient receive Postoperative adjuvant chemotherapy le 6 week . Shorter 4 week operation ; 3 . Patient inadequate Blood system , liver function renal function . 4 . Brain metastasis symptom 5 . Patient arrhythmia , myocardial ischemia , serious atrioventricular block , inadequate cardiac function , serious valvular heart disease ; 6 . Chronic enteritis intestinal obstruction 7 . Bone marrow failure 8 . Mental disease difficult control 9 . Participated clinic trial within 3 month 10 . Pregnant lactation patient 11 . The researcher evaluate patient suitable trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Mirtazapine</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>placebo</keyword>
	<keyword>RCT</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>